Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Terbinafine – systemic use

Classification: A

Drug products: Azurifin, Lamisil®, Terbinafin 2care4, Terbinafin Arrow, Terbinafin Bluefish, Terbinafin Ebb, Terbinafin Hexal, Terbinafin Medical Valley, Terbinafin Mylan, Terbinafin Orifarm, Terbinafin ratiopharm, Terbinafin STADA

ATC code: D01BA02


Men and women have similar effect of terbinafine for treatment of toenail onychomycosis.

Additional information

Most  published studies show a higher prevalence of onychomycosis in men. However, the male/female ratio varies between study population and study types. In population-based studies, the male/female ratio was 1.6. In hospital-based studies, the male/female ratio was 1.9 in North America, 1.5 in Europe, 0.8 in South America [1].

Pharmacokinetics and dosing

No studies with a sex analysis regarding the pharmacokinetics or dosing of terbinafine have been found.


No sex differences in patient-reported outcomes were shown after 12 weeks of treatment with oral terbinafine 250 mg/day in patients with toenail onychomycosis (309 men, 195 women) [2]. Also, another smaller study in patients with toenail onychomycosis treated with terbinafine 250 mg/day for 12 weeks (40 men, 34 women) showed no sex differences in mycological cure (defined as negative 20% KOH test and a negative mycological culture) [3].

Adverse effects

No studies with a sex analysis regarding adverse effects of terbinafine have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2022-11-08

Date of litterature search: 2022-09-16


  1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28:1480-91. PubMed
  2. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52. PubMed
  3. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14:237-42. PubMed
  4. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg, Pauline Raaschou, Carl-Olav Stiller

Approved by: Karin Schenck-Gustafsson